阿托伐他汀对鼠脑缺血再灌注后P-选择素、人髓过氧化物酶的影响

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (12): 1335-1339.

阿托伐他汀对鼠脑缺血再灌注后P-选择素、人髓过氧化物酶的影响

倪红¹, 储照虎², 刘新亚³

¹温州医学院附属台州医院神经内科, 台州 317000, 浙江;
²皖南医学院弋矶山医院神经内科, 芜湖 241001, 安徽;
³天长县人民医院, 天长 239300, 安徽

收稿日期:2009-08-03 修回日期:2009-10-15 发布日期:2020-10-20
作者简介:倪红, 硕士, 医师, 研究方向:脑血管病。Tel:13676652525 E-mail:yini060125@163.com.cn

Effects of atorvastatin on P-selectin and MPO in cerebral ischemia reperfusion rats

NI Hong¹, CHU Zhao-hu², LIU Xin-ya³

¹Departnent of Nerves Internal Medicine of Taizhou Hospital Affiliated Wenzhou Medical College, Wenzhou 317000,Zhejiang, China;
²Departnent of Nerves Internal Medicine of Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China;
³Tianchang People's Hospital, Tianchan 236300, Anhui, China

Received:2009-08-03 Revised:2009-10-15 Published:2020-10-20

摘要/Abstract

摘要： 目的：观察阿托伐他汀对P-selectin 表达及人髓过氧化物酶( MPO) 的影响。方法：将SD 大鼠随机分为假手术组( Sham) 、脑缺血再灌注组(CIR) 、阿托伐他汀组( ATO) 。阿托伐他汀采用灌胃的方式给药。CIR 组按制作模型后断头时程不同又分为6 、12 、24 、48 、72 h 共5 个亚组。阿托伐他汀组按给药时间不同分为给药4 周、2 周、3 d和造模后即时组4 个亚组, 每亚组分别于造模后12 、24 h 检测。断头取脑, 制作标本, 连续切片作P-selectin 免疫组化染色, 脑组织匀浆测定MPO 。结果：CIR 组可见P-selectin 阳性表达血管数6 h开始上升, 12 h 达到高峰, 至第3 天仍有少量表达, 阿托伐他汀进行干预后, P-selectin 表达明显下调( P <0.01), 阿托伐他汀组内两两比较差异亦有统计学意义( P <0.01);各CIR 组MPO 含量明显高于Sham 组( P <0.01), P-selectin 表达与MPO含量呈线性正相关, 给阿托伐他汀、阿司匹林干预后脑组织匀浆MPO 含量下降, 阿托伐他汀组内两两比较差异亦有统计学意义( P <0.05) 。结论：脑缺血再灌注后P-selectin 表达和MPO 含量明显升高, 使用阿托伐他汀干预后P-selectin 、MPO 含量明显下降。

关键词: 脑缺血再灌注, P-selectin, 人髓过氧化物酶, 阿托伐他汀

Abstract: AIM: To observe the effects on the expressions of P-selectin and MPO induced by cerebral ischemia reperfusion injury in the rats after using atorvastatin.METHODS: SD rats were randomly divideded into sham operation group( Sham), cerebral ischemia reperfusion group( CIR) and atorvastatin group( ATO). Aatorvastatin was given via intragastrical.ATO group were divided into four weeks, two weeks, three days later and the immediate subgroup.Sham and CIR groups were divided into 6, 12, 24, 48, 72 hours subgroups, and were examined 12, 24 hours later.The expressions of P-selectin by immunohistochemistry technique and the contents of MPO in brain tissue homogenate were detected.RESULTS: The expressions of Pselectin were increased obviously at 6 h after ischemia reperfusion, the peak was at 12 h, then gradually were decreased, small amounts were expressed at 3 d.The expressions of P-selectin were down-regulation, after using atorvastatin, and there were remarkable differences in ATO group ( P <0.01).Compared with Sham group, the contents of MPO were increased remarkably in CIR group ( P <0.01).There was a linear positive correlation between the expressions of P-selectin and the contents of MPO.The contents of MPO in brain homogenate were decreased treated with atorvastatin and acenterine.There was statistical significance within ATO group( P <0.05).CONCLUSION: The expressions of P-selectin and the contents of MPO are increased after cerebral ischemia reperfusion, and decreased after using atorvastatin ( r =0.883, P < 0.05).

Key words: cerebral ischemia reperfusion, P-selectin, myeloperoxidase, atorvastatin

中图分类号:

R965.2

倪红, 储照虎, 刘新亚. 阿托伐他汀对鼠脑缺血再灌注后P-选择素、人髓过氧化物酶的影响[J]. 中国临床药理学与治疗学, 2009, 14(12): 1335-1339.

NI Hong, CHU Zhao-hu, LIU Xin-ya. Effects of atorvastatin on P-selectin and MPO in cerebral ischemia reperfusion rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1335-1339.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[3]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[4]	张高娇，王芯芯，周佳，王雷雷，戴勤学. 小窝蛋白Cav-1介导人参皂苷Rb1对小鼠脑缺血再灌注损伤的脑保护作用[J]. 中国临床药理学与治疗学, 2020, 25(3): 265-270.
[5]	肖世庚，董文彬，叶小弟，陈爱瑛，程敏，缪云萍，郑高利. 自噬在米诺环素保护大鼠脑缺血再灌注损伤中的作用研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 730-736.
[6]	俞陈陈，刘树群，刘建龙，曹红，刘雪娇，蔡茜茜. 姜黄素对高血压病大鼠全脑缺血再灌注时海马神经元损伤及皮质酮、SGK1表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(7): 737-743.
[7]	段晋宁, 向常清, 钱爱红, 李进, 陈修全, 韩永峰, 黄娜, 范丽莉. 珠子参皂苷通过激活 PI3K/Akt通路对小鼠脑缺血再灌注损伤的保护作用研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 750-758.
[8]	刘小艳，田野，刘骥飞，苏刚，张振昶. 姜黄素对脑缺血再灌注损伤的保护作用机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(11): 1305-1309.
[9]	黄立佳，黄杨，孔劲松，郑鑫，宫小康，阮建伟，王海宝. 阿托伐他汀钙经STAT1-caspase-3信号轴抑制膝骨关节炎大鼠关节软骨退变的研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 743-748.
[10]	徐慧，张民远，戴勤学. miR-145通过调节SOD活性介导人参皂苷Rb1对脑缺血再灌注损伤大鼠的脑保护作用[J]. 中国临床药理学与治疗学, 2018, 23(11): 1215-1220.
[11]	杨亚楠，陈莉梅，陶春蕾. 阿托伐他汀钙片在中国健康受试者的生物等效性试验[J]. 中国临床药理学与治疗学, 2018, 23(11): 1258-1264.
[12]	武彩霞，杜冠华. 匹诺塞林对脑缺血再灌注内质网应激凋亡相关基因mRNA表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(1): 34-40.
[13]	朱洁瑾，吴湧，叶晓莉，叶华进，王刚，费霏，李晴宇. 漆黄素对脑缺血再灌注诱导学习记忆损伤及HPA轴的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1002-1007.
[14]	谢跃武，张芳，郭岩. 小鼠大脑中动脉栓塞模型脑血流量与梗死体积相关性分析[J]. 中国临床药理学与治疗学, 2017, 22(5): 501-506.
[15]	樊开宇，王冰，梅骁乐，陈志武. 滁菊总黄酮对大鼠脑缺血再灌注损伤的保护作用[J]. 中国临床药理学与治疗学, 2017, 22(1): 9-12.